| Lymphoma, Follicular
Epkinly vs Tazverik
Side-by-side clinical, coverage, and cost comparison for lymphoma, follicular.Deep comparison between: Epkinly vs Tazverik with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTazverik has a higher rate of injection site reactions vs Epkinly based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tazverik but not Epkinly, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Epkinly
Tazverik
At A Glance
SC injection
Every 1-4 weeks
CD20xCD3 bispecific antibody
Oral
Twice daily
EZH2 methyltransferase inhibitor
Indications
- Diffuse Large B-Cell Lymphoma
- High grade B-cell lymphoma
- Lymphoma, Follicular
- Sarcoma, Epithelioid
- Lymphoma, Follicular
Dosing
Diffuse Large B-Cell Lymphoma, High grade B-cell lymphoma Step-up SC doses: 0.16 mg (Day 1), 0.8 mg (Day 8); then 48 mg weekly through Cycle 3; 48 mg every 2 weeks for Cycles 4-9; 48 mg monthly from Cycle 10 until disease progression or unacceptable toxicity.
Lymphoma, Follicular (monotherapy) Step-up SC doses: 0.16 mg (Day 1), 0.8 mg (Day 8), 3 mg (Day 15); then 48 mg weekly through Cycle 3; 48 mg every 2 weeks for Cycles 4-9; 48 mg monthly from Cycle 10 until disease progression or unacceptable toxicity.
Lymphoma, Follicular (+ lenalidomide and rituximab) Step-up SC doses: 0.16 mg (Day 1), 0.8 mg (Day 8), 3 mg (Day 15); then 48 mg weekly through Cycle 3; 48 mg monthly for Cycles 4-12 with lenalidomide 20 mg (Days 1-21) and rituximab 375 mg/m2 (Cycles 1-5); total 12 cycles or until progression.
Sarcoma, Epithelioid 800 mg orally twice daily with or without food until disease progression or unacceptable toxicity.
Lymphoma, Follicular 800 mg orally twice daily with or without food until disease progression or unacceptable toxicity; select patients based on EZH2 mutation of codons Y646, A682, or A692 for EZH2-mutant R/R FL.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) CRS, fatigue, injection site reactions, musculoskeletal pain, pyrexia, abdominal pain, nausea, diarrhea, rash, upper respiratory tract infections, constipation, pneumonia, COVID-19, fever, cough, headache
Serious CRS, infections (sepsis, COVID-19, pneumonia, upper respiratory tract infections), pleural effusion, febrile neutropenia, fever, ICANS
Postmarketing Hemophagocytic Lymphohistiocytosis (HLH)
Most common (>=20%) - Sarcoma, Epithelioid pain, fatigue, nausea, decreased appetite, vomiting, constipation
Most common (>=20%) - Lymphoma, Follicular fatigue, upper respiratory tract infection, musculoskeletal pain, nausea, abdominal pain
Serious - Sarcoma, Epithelioid hemorrhage, pleural effusion, skin infection, dyspnea, pain, respiratory distress
Serious - Lymphoma, Follicular general physical health deterioration, abdominal pain, pneumonia, sepsis, anemia
Pharmacology
Epcoritamab-bysp is a bispecific CD20-directed CD3 T-cell engager (humanized IgG1) that simultaneously binds CD3 on T-cells and CD20 on lymphoma and healthy B-lineage cells, activating T-cells, inducing cytokine release, and causing B-cell lysis; in combination with rituximab it also mediates NK cell antibody-dependent cellular cytotoxicity (ADCC).
Tazemetostat is a selective inhibitor of EZH2 methyltransferase and certain gain-of-function mutations (Y646X, A682G, A692V), blocking trimethylation of histone H3 lysine 27 and relieving transcriptional repression that drives tumor growth in epithelioid sarcoma (via SWI/SNF complex dysfunction) and B-cell lymphoma with or without EZH2 mutation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Epkinly
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Tazverik
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (3/12)
UnitedHealthcare
Epkinly
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Tazverik
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Epkinly
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Tazverik
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableGenmab Patient Assistance Program: Epkinly
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableCancerCare: Non-Hodgkin Lymphoma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EpkinlyView full Epkinly profile
TazverikView full Tazverik profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.